basal insulin with glp 1 Adding a GLP-1 receptor agonist was not associated a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation Clinical Focus on GLP-1 Agonists

Omada Health, a multi-condition virtual care provider with over 12 years of experience, partnered with Express Scripts by Evernorth to learn more

The rapid weight loss achieved with GLP-1 medications may affect nutrient absorption and overall nutritional status, potentially impacting the bodys ability to maintain healthy teeth and gums

Ferrari, E

The SURMOUNT trial program provides extensive data on what tirzepatide achieves without any additional weight loss medication: 5 mg dose: 15.0% average weight loss at 72 weeks 10 mg dose: 19.5% average weight loss at 72 weeks 15 mg dose: 20.9% average weight loss at 72 weeks At 15 mg, 56.1% of participants lost at least 20% of body weight At 15 mg, 38.7% of participants lost at least 25% of body weight These numbers are remarkable

May cause serious toxicity if levels become too high

This leaves the thyroid vulnerable